ResearcherSorbonne UniversitéActive in the last 2 years
Solène Doat
Matched on ORCID iD 0000-0003-4396-5622; OpenAlex author ID A5014967767. Sources: OpenAlex.
Their work
- Papers
- 7
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 28
2014: 1 paper · 2015: none · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 7
- Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41598-025-13160-7↗
- Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective… Co-author DOI 10.1016/j.ejca.2024.115051↗
- Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma? Co-author DOI 10.1016/j.dld.2022.01.126↗
- Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Co-author DOI 10.1038/s41416-021-01624-2↗
- Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. Co-author DOI 10.1016/j.clinre.2020.08.016↗
- Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. Co-author DOI 10.1158/1078-0432.ccr-16-0806↗
- Unbalance between plasma levels of Protein Z and protein Z-dependent inhibitor in patients with colorectal and pancreatic cancer: a pilot study. Co-author DOI 10.1016/j.thromres.2013.11.015↗
Closest collaborators
The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Daniel Pietrasz · 5 shared papers, 2017–2025 · strength 0.74
- Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
- Paper Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic… DOI 10.1016/j.dld.2022.01.126↗
- Paper Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical … DOI 10.1038/s41416-021-01624-2↗
- Jean‐Baptiste Bachet · 5 shared papers, 2017–2025 · strength 0.74
- Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
- Paper Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic… DOI 10.1016/j.dld.2022.01.126↗
- Paper Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical … DOI 10.1038/s41416-021-01624-2↗
- Pierre Laurent‐Puig · 4 shared papers, 2017–2025 · strength 0.62
- Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
- Paper Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic… DOI 10.1016/j.dld.2022.01.126↗
- Paper Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical … DOI 10.1038/s41416-021-01624-2↗
- Olivier Caliez · 2 shared papers, 2022–2025 · strength 0.43
- Paper Correlation between circulating tumor DNA quantity assessed by methylated markers and tumor volume in patients with met… DOI 10.1038/s41598-025-13160-7↗
- Paper Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic… DOI 10.1016/j.dld.2022.01.126↗
- Julien Taı̈eb · 2 shared papers, 2022–2024 · strength 0.29
- Paper Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination de… DOI 10.1016/j.ejca.2024.115051↗
- Paper Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical … DOI 10.1038/s41416-021-01624-2↗
- Isabelle Trouilloud · 2 shared papers, 2021–2024 · strength 0.28
- Paper Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination de… DOI 10.1016/j.ejca.2024.115051↗
- Paper Prognostic value of the early change in neutrophil-to-lymphocyte ratio in metastatic pancreatic adenocarcinoma. DOI 10.1016/j.clinre.2020.08.016↗
- Léo Mas · 1 shared paper, 2025 · strength 0.27
- Mathilde Wagner · 1 shared paper, 2025 · strength 0.27
- Jeannie M'Baloula · 1 shared paper, 2024 · strength 0.16
- Anna Pellat · 1 shared paper, 2024 · strength 0.16
- Jean‐Frédéric Blanc · 1 shared paper, 2024 · strength 0.16
- Marie Müller · 1 shared paper, 2024 · strength 0.16
- Anthony Turpin · 1 shared paper, 2024 · strength 0.16
- Anne‐Laure Védié · 1 shared paper, 2024 · strength 0.16
- Alice Boilève · 1 shared paper, 2024 · strength 0.16
- Louis de Mestier · 1 shared paper, 2024 · strength 0.16
- David Tougeron · 1 shared paper, 2024 · strength 0.16
- François‐Xavier Caroli‐Bosc · 1 shared paper, 2024 · strength 0.16
- Olivier Bouché · 1 shared paper, 2024 · strength 0.16
- Yves Rinaldi · 1 shared paper, 2022 · strength 0.13
- Laëtitia Dahan · 1 shared paper, 2022 · strength 0.13
- Jean–Marc Phelip · 1 shared paper, 2022 · strength 0.13
- Déwi Vernerey · 1 shared paper, 2021 · strength 0.12
- Paul McLellan · 1 shared paper, 2021 · strength 0.12
- Christophe Louvet · 1 shared paper, 2021 · strength 0.12
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.